Clinical Trial: Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Twenty-Eight Week, Open-Label, Safety Study of Flibanserin 50 Mgs to 100 Mgs Daily in Premenopausal European Women With HSDD

Brief Summary: Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens

Detailed Summary:
Sponsor: Sprout Pharmaceuticals, Inc

Current Primary Outcome: Frequency of Adverse Events [ Time Frame: 28 weeks ]

Original Primary Outcome: adverse events

Current Secondary Outcome:

Original Secondary Outcome: FSFI desire subscale, FSDS R, PGI Improvement, CGI Improvement, Patient Benefit Evaluation

Information By: Sprout Pharmaceuticals, Inc

Dates:
Date Received: January 15, 2008
Date Started: January 2008
Date Completion:
Last Updated: May 20, 2014
Last Verified: May 2014